In December of 2019, Health and Human Services and the FDA issued a joint proposed rule which would allow for the importation of pharmaceuticals from Canada at the sole discretion of HHS. With the final rule issued in December, HHS now allows importation of these products assuming the product poses no threat to the health and safety of the American public.

On May 25, 2021, James W. Kim will be a panelist on the Rx Pricing and Reimbursement Summit – Analyze the Final Rule on the Importation of Pharmaceuticals conference that will:

• Discuss the effects on US manufacturers based on the pricing differential with Canadian pharmaceuticals and the cost savings involved
• Examine the legislative action states are taking to allow for the importation of pharmaceutical products
• Review the response from US manufacturers to the implementation of the rule 

For more details and to register click here.